Microscopic image of a Merkel cell carcinoma (Shutterstock)
June 9, 2025 01:21 PM EDTUpdated 03:08 PM
Bioregnum
R&D

Fed­er­al­ly-fund­ed can­cer re­search comes to a per­ilous cross­roads

Paul Nghiem and the physi­cian-sci­en­tists who make up the Merkel Cell Car­ci­no­ma Col­lab­o­ra­tive (MC3) In­sti­tute have a lot rid­ing on an up­com­ing de­ci­sion at the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Up­dat­ed: HHS chief Kennedy re­moves all ACIP mem­bers, dis­man­tling vac­cine board

Biotech slump forces Re­silience to wind down six man­u­fac­tur­ing sites, us­ing bank­rupt­cy move

Up­dat­ed: Mer­ck wins FDA ap­proval for RSV an­ti­body drug, mak­ing a hot mar­ket more com­pet­i­tive

Mer­ck says its oral PC­SK9 in­hibitor ‘sig­nif­i­cant­ly’ cut cho­les­terol in two Phase 3 tri­als

In a break from oth­er biotechs, Twist Bio­science throws sup­port be­hind tar­iffs on syn­thet­ic DNA

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times